Nuveen Asset Management Portfolio holdings
Nuveen Asset Management, founded in 1898 by John Nuveen and headquartered in Chicago, Illinois, is a leading global investment manager and subsidiary of TIAA, overseeing hundreds of billions in assets with a focus on fixed income, equities, and sustainable investing. Initially known for municipal bonds, Nuveen has expanded into a broad range of strategies, including mutual funds, ETFs, closed-end funds, and private capital solutions, serving institutional investors, financial advisors, and individuals. The firm emphasizes income-generating investments and ESG (environmental, social, governance) integration, leveraging its deep research capabilities and a century-long legacy in the bond market. With a strong presence in North America and growing international reach, Nuveen blends tradition with innovation to meet diverse client needs in the evolving investment landscape.
Top Buys
| 1 |
Meta Platforms (Facebook)
META
|
+$1.34B |
| 2 |
NVIDIA
NVDA
|
+$546M |
| 3 |
Boeing
BA
|
+$405M |
| 4 |
Linde
LIN
|
+$405M |
| 5 |
Exxon Mobil
XOM
|
+$316M |
Top Sells
| 1 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$1.42B |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$319M |
| 3 |
Microsoft
MSFT
|
+$292M |
| 4 |
Accenture
ACN
|
+$277M |
| 5 |
Lam Research
LRCX
|
+$271M |
Sector Composition
| 1 | Technology | 26.07% |
| 2 | Healthcare | 13.09% |
| 3 | Financials | 11.54% |
| 4 | Consumer Discretionary | 10.68% |
| 5 | Industrials | 8.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2901
Mineralys Therapeutics
MLYS
$3.09B
| $253K | ﹤0.01% |
+16,134
| New | +$253K |
|
2902
OppFi
OPFI
$343M
| $251K | ﹤0.01% |
122,239
-2,999
| -2% | -$6.16K |
|
2903
Vanguard Growth ETF
VUG
$194B
| $251K | ﹤0.01% |
+1,005
| New | +$251K |
|
|
AFMD
2904
DELISTED
Affimed
AFMD
| $248K | ﹤0.01% |
33,205
-287
| -0.9% | -$2.14K |
|
2905
Aemetis
AMTX
$153M
| $248K | ﹤0.01% |
107,072
-17,349
| -14% | -$40.2K |
|
2906
GeneDx Holdings
WGS
$3.75B
| $248K | ﹤0.01% |
20,554
+5,131
| +33% | +$61.9K |
|
|
CELL
2907
DELISTED
PhenomeX Inc. Common Stock
CELL
| $248K | ﹤0.01% |
214,012
-2,115
| -1% | -$2.45K |
|
|
ALPN
2908
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $245K | ﹤0.01% |
31,729
| – | – |
|
2909
Invivyd
IVVD
$262M
| $244K | ﹤0.01% |
203,878
+5,440
| +3% | +$6.51K |
|
2910
Superior Group of Companies
SGC
$191M
| $243K | ﹤0.01% |
30,823
-12,111
| -28% | -$95.5K |
|
|
MKFG
2911
DELISTED
Markforged Holding Corporation
MKFG
| $242K | ﹤0.01% |
25,221
-2,604
| -9% | -$25K |
|
|
AKYA
2912
DELISTED
Akoya BioSciences
AKYA
| $240K | ﹤0.01% |
29,374
-246
| -0.8% | -$2.01K |
|
2913
Plains All American Pipeline
PAA
$12.2B
| $240K | ﹤0.01% |
19,210
-307
| -2% | -$3.84K |
|
2914
PCB Bancorp
PCB
$317M
| $238K | ﹤0.01% |
16,442
| – | – |
|
2915
Red Violet
RDVT
$714M
| $236K | ﹤0.01% |
13,408
| – | – |
|
2916
Colony Bankcorp
CBAN
$319M
| $235K | ﹤0.01% |
23,042
-13,351
| -37% | -$136K |
|
2917
Repare Therapeutics
RPTX
$75.6M
| $235K | ﹤0.01% |
23,846
+2,216
| +10% | +$21.8K |
|
|
ICVX
2918
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $235K | ﹤0.01% |
40,511
-14,310
| -26% | -$83K |
|
2919
First Bank
FRBA
$422M
| $233K | ﹤0.01% |
23,105
-11,964
| -34% | -$121K |
|
2920
NI Holdings
NODK
$293M
| $232K | ﹤0.01% |
17,869
-10,188
| -36% | -$132K |
|
2921
Concrete Pumping Holdings
BBCP
$376M
| $231K | ﹤0.01% |
33,946
-30
| -0.1% | -$204 |
|
2922
Hydrofarm Holdings
HYFM
$15.1M
| $230K | ﹤0.01% |
13,266
+1,182
| +10% | +$20.5K |
|
2923
Bank of America Series L
BAC.PRL
$3.97B
| – | – |
0
| – | -$224K |
|
|
AC
2924
DELISTED
Associated Capital Group
AC
| $224K | ﹤0.01% |
6,059
-5,017
| -45% | -$185K |
|
|
JNCE
2925
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $223K | ﹤0.01% |
120,810
-10,575
| -8% | -$19.5K |
|